Medical Care
Global Lipid Nanoparticles (LNPs) CDMO Service Market Research Report 2025
- May 12, 25
- ID: 235924
- Pages: 83
- Figures: 87
- Views: 27
The global market for Lipid Nanoparticles (LNPs) CDMO Service was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Lipid Nanoparticles (LNPs) CDMO Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Lipid Nanoparticles (LNPs) CDMO Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Lipid Nanoparticles (LNPs) CDMO Service in Vaccines and Drugs is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Lipid Nanoparticles (LNPs) CDMO Service include Evonik, Lonza, Rentschler Biopharma, Samsung Biologics, Hanmi Pharmaceutical, Catalent Biologics, FUJIFILM Pharmaceuticals, CordenPharma, ST Pharm, eTheRNA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Lipid Nanoparticles (LNPs) CDMO Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lipid Nanoparticles (LNPs) CDMO Service.
The Lipid Nanoparticles (LNPs) CDMO Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lipid Nanoparticles (LNPs) CDMO Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lipid Nanoparticles (LNPs) CDMO Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Evonik
Lonza
Rentschler Biopharma
Samsung Biologics
Hanmi Pharmaceutical
Catalent Biologics
FUJIFILM Pharmaceuticals
CordenPharma
ST Pharm
eTheRNA
Esco Aster
Recipharm
Yuantai Biological Technology
GenScript Biotechnology
WuXi Biologics
Segment by Type
mRNA-LNP CDMO
siRNA-LNP CDMO
pDNA-LNP CDMO
Others
Segment by Application
Vaccines and Drugs
Diagnostics and Medical Imaging
Nanotherapeutics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lipid Nanoparticles (LNPs) CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Lipid Nanoparticles (LNPs) CDMO Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Lipid Nanoparticles (LNPs) CDMO Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Lipid Nanoparticles (LNPs) CDMO Service in Vaccines and Drugs is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Lipid Nanoparticles (LNPs) CDMO Service include Evonik, Lonza, Rentschler Biopharma, Samsung Biologics, Hanmi Pharmaceutical, Catalent Biologics, FUJIFILM Pharmaceuticals, CordenPharma, ST Pharm, eTheRNA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Lipid Nanoparticles (LNPs) CDMO Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lipid Nanoparticles (LNPs) CDMO Service.
The Lipid Nanoparticles (LNPs) CDMO Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lipid Nanoparticles (LNPs) CDMO Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lipid Nanoparticles (LNPs) CDMO Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Evonik
Lonza
Rentschler Biopharma
Samsung Biologics
Hanmi Pharmaceutical
Catalent Biologics
FUJIFILM Pharmaceuticals
CordenPharma
ST Pharm
eTheRNA
Esco Aster
Recipharm
Yuantai Biological Technology
GenScript Biotechnology
WuXi Biologics
Segment by Type
mRNA-LNP CDMO
siRNA-LNP CDMO
pDNA-LNP CDMO
Others
Segment by Application
Vaccines and Drugs
Diagnostics and Medical Imaging
Nanotherapeutics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lipid Nanoparticles (LNPs) CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 mRNA-LNP CDMO
1.2.3 siRNA-LNP CDMO
1.2.4 pDNA-LNP CDMO
1.2.5 Others
1.3 Market by Application
1.3.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Vaccines and Drugs
1.3.3 Diagnostics and Medical Imaging
1.3.4 Nanotherapeutics
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Perspective (2020-2031)
2.2 Global Lipid Nanoparticles (LNPs) CDMO Service Growth Trends by Region
2.2.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Lipid Nanoparticles (LNPs) CDMO Service Historic Market Size by Region (2020-2025)
2.2.3 Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Region (2026-2031)
2.3 Lipid Nanoparticles (LNPs) CDMO Service Market Dynamics
2.3.1 Lipid Nanoparticles (LNPs) CDMO Service Industry Trends
2.3.2 Lipid Nanoparticles (LNPs) CDMO Service Market Drivers
2.3.3 Lipid Nanoparticles (LNPs) CDMO Service Market Challenges
2.3.4 Lipid Nanoparticles (LNPs) CDMO Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lipid Nanoparticles (LNPs) CDMO Service Players by Revenue
3.1.1 Global Top Lipid Nanoparticles (LNPs) CDMO Service Players by Revenue (2020-2025)
3.1.2 Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Players (2020-2025)
3.2 Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Lipid Nanoparticles (LNPs) CDMO Service Revenue
3.4 Global Lipid Nanoparticles (LNPs) CDMO Service Market Concentration Ratio
3.4.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lipid Nanoparticles (LNPs) CDMO Service Revenue in 2024
3.5 Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service Head office and Area Served
3.6 Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Product and Application
3.7 Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Lipid Nanoparticles (LNPs) CDMO Service Breakdown Data by Type
4.1 Global Lipid Nanoparticles (LNPs) CDMO Service Historic Market Size by Type (2020-2025)
4.2 Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Type (2026-2031)
5 Lipid Nanoparticles (LNPs) CDMO Service Breakdown Data by Application
5.1 Global Lipid Nanoparticles (LNPs) CDMO Service Historic Market Size by Application (2020-2025)
5.2 Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
6.2 North America Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025)
6.4 North America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
7.2 Europe Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025)
7.4 Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
8.2 Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2020-2025)
8.4 Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
9.2 Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025)
9.4 Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
10.2 Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025)
10.4 Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Evonik
11.1.1 Evonik Company Details
11.1.2 Evonik Business Overview
11.1.3 Evonik Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.1.4 Evonik Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.1.5 Evonik Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.2.4 Lonza Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.2.5 Lonza Recent Development
11.3 Rentschler Biopharma
11.3.1 Rentschler Biopharma Company Details
11.3.2 Rentschler Biopharma Business Overview
11.3.3 Rentschler Biopharma Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.3.4 Rentschler Biopharma Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.3.5 Rentschler Biopharma Recent Development
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Details
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.4.4 Samsung Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.4.5 Samsung Biologics Recent Development
11.5 Hanmi Pharmaceutical
11.5.1 Hanmi Pharmaceutical Company Details
11.5.2 Hanmi Pharmaceutical Business Overview
11.5.3 Hanmi Pharmaceutical Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.5.4 Hanmi Pharmaceutical Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.5.5 Hanmi Pharmaceutical Recent Development
11.6 Catalent Biologics
11.6.1 Catalent Biologics Company Details
11.6.2 Catalent Biologics Business Overview
11.6.3 Catalent Biologics Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.6.4 Catalent Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.6.5 Catalent Biologics Recent Development
11.7 FUJIFILM Pharmaceuticals
11.7.1 FUJIFILM Pharmaceuticals Company Details
11.7.2 FUJIFILM Pharmaceuticals Business Overview
11.7.3 FUJIFILM Pharmaceuticals Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.7.4 FUJIFILM Pharmaceuticals Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.7.5 FUJIFILM Pharmaceuticals Recent Development
11.8 CordenPharma
11.8.1 CordenPharma Company Details
11.8.2 CordenPharma Business Overview
11.8.3 CordenPharma Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.8.4 CordenPharma Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.8.5 CordenPharma Recent Development
11.9 ST Pharm
11.9.1 ST Pharm Company Details
11.9.2 ST Pharm Business Overview
11.9.3 ST Pharm Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.9.4 ST Pharm Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.9.5 ST Pharm Recent Development
11.10 eTheRNA
11.10.1 eTheRNA Company Details
11.10.2 eTheRNA Business Overview
11.10.3 eTheRNA Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.10.4 eTheRNA Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.10.5 eTheRNA Recent Development
11.11 Esco Aster
11.11.1 Esco Aster Company Details
11.11.2 Esco Aster Business Overview
11.11.3 Esco Aster Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.11.4 Esco Aster Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.11.5 Esco Aster Recent Development
11.12 Recipharm
11.12.1 Recipharm Company Details
11.12.2 Recipharm Business Overview
11.12.3 Recipharm Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.12.4 Recipharm Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.12.5 Recipharm Recent Development
11.13 Yuantai Biological Technology
11.13.1 Yuantai Biological Technology Company Details
11.13.2 Yuantai Biological Technology Business Overview
11.13.3 Yuantai Biological Technology Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.13.4 Yuantai Biological Technology Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.13.5 Yuantai Biological Technology Recent Development
11.14 GenScript Biotechnology
11.14.1 GenScript Biotechnology Company Details
11.14.2 GenScript Biotechnology Business Overview
11.14.3 GenScript Biotechnology Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.14.4 GenScript Biotechnology Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.14.5 GenScript Biotechnology Recent Development
11.15 WuXi Biologics
11.15.1 WuXi Biologics Company Details
11.15.2 WuXi Biologics Business Overview
11.15.3 WuXi Biologics Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.15.4 WuXi Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.15.5 WuXi Biologics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 mRNA-LNP CDMO
1.2.3 siRNA-LNP CDMO
1.2.4 pDNA-LNP CDMO
1.2.5 Others
1.3 Market by Application
1.3.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Vaccines and Drugs
1.3.3 Diagnostics and Medical Imaging
1.3.4 Nanotherapeutics
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Perspective (2020-2031)
2.2 Global Lipid Nanoparticles (LNPs) CDMO Service Growth Trends by Region
2.2.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Lipid Nanoparticles (LNPs) CDMO Service Historic Market Size by Region (2020-2025)
2.2.3 Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Region (2026-2031)
2.3 Lipid Nanoparticles (LNPs) CDMO Service Market Dynamics
2.3.1 Lipid Nanoparticles (LNPs) CDMO Service Industry Trends
2.3.2 Lipid Nanoparticles (LNPs) CDMO Service Market Drivers
2.3.3 Lipid Nanoparticles (LNPs) CDMO Service Market Challenges
2.3.4 Lipid Nanoparticles (LNPs) CDMO Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lipid Nanoparticles (LNPs) CDMO Service Players by Revenue
3.1.1 Global Top Lipid Nanoparticles (LNPs) CDMO Service Players by Revenue (2020-2025)
3.1.2 Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Players (2020-2025)
3.2 Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Lipid Nanoparticles (LNPs) CDMO Service Revenue
3.4 Global Lipid Nanoparticles (LNPs) CDMO Service Market Concentration Ratio
3.4.1 Global Lipid Nanoparticles (LNPs) CDMO Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lipid Nanoparticles (LNPs) CDMO Service Revenue in 2024
3.5 Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service Head office and Area Served
3.6 Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Product and Application
3.7 Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Lipid Nanoparticles (LNPs) CDMO Service Breakdown Data by Type
4.1 Global Lipid Nanoparticles (LNPs) CDMO Service Historic Market Size by Type (2020-2025)
4.2 Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Type (2026-2031)
5 Lipid Nanoparticles (LNPs) CDMO Service Breakdown Data by Application
5.1 Global Lipid Nanoparticles (LNPs) CDMO Service Historic Market Size by Application (2020-2025)
5.2 Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
6.2 North America Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025)
6.4 North America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
7.2 Europe Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025)
7.4 Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
8.2 Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2020-2025)
8.4 Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
9.2 Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025)
9.4 Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size (2020-2031)
10.2 Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025)
10.4 Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Evonik
11.1.1 Evonik Company Details
11.1.2 Evonik Business Overview
11.1.3 Evonik Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.1.4 Evonik Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.1.5 Evonik Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.2.4 Lonza Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.2.5 Lonza Recent Development
11.3 Rentschler Biopharma
11.3.1 Rentschler Biopharma Company Details
11.3.2 Rentschler Biopharma Business Overview
11.3.3 Rentschler Biopharma Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.3.4 Rentschler Biopharma Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.3.5 Rentschler Biopharma Recent Development
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Details
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.4.4 Samsung Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.4.5 Samsung Biologics Recent Development
11.5 Hanmi Pharmaceutical
11.5.1 Hanmi Pharmaceutical Company Details
11.5.2 Hanmi Pharmaceutical Business Overview
11.5.3 Hanmi Pharmaceutical Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.5.4 Hanmi Pharmaceutical Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.5.5 Hanmi Pharmaceutical Recent Development
11.6 Catalent Biologics
11.6.1 Catalent Biologics Company Details
11.6.2 Catalent Biologics Business Overview
11.6.3 Catalent Biologics Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.6.4 Catalent Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.6.5 Catalent Biologics Recent Development
11.7 FUJIFILM Pharmaceuticals
11.7.1 FUJIFILM Pharmaceuticals Company Details
11.7.2 FUJIFILM Pharmaceuticals Business Overview
11.7.3 FUJIFILM Pharmaceuticals Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.7.4 FUJIFILM Pharmaceuticals Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.7.5 FUJIFILM Pharmaceuticals Recent Development
11.8 CordenPharma
11.8.1 CordenPharma Company Details
11.8.2 CordenPharma Business Overview
11.8.3 CordenPharma Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.8.4 CordenPharma Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.8.5 CordenPharma Recent Development
11.9 ST Pharm
11.9.1 ST Pharm Company Details
11.9.2 ST Pharm Business Overview
11.9.3 ST Pharm Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.9.4 ST Pharm Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.9.5 ST Pharm Recent Development
11.10 eTheRNA
11.10.1 eTheRNA Company Details
11.10.2 eTheRNA Business Overview
11.10.3 eTheRNA Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.10.4 eTheRNA Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.10.5 eTheRNA Recent Development
11.11 Esco Aster
11.11.1 Esco Aster Company Details
11.11.2 Esco Aster Business Overview
11.11.3 Esco Aster Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.11.4 Esco Aster Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.11.5 Esco Aster Recent Development
11.12 Recipharm
11.12.1 Recipharm Company Details
11.12.2 Recipharm Business Overview
11.12.3 Recipharm Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.12.4 Recipharm Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.12.5 Recipharm Recent Development
11.13 Yuantai Biological Technology
11.13.1 Yuantai Biological Technology Company Details
11.13.2 Yuantai Biological Technology Business Overview
11.13.3 Yuantai Biological Technology Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.13.4 Yuantai Biological Technology Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.13.5 Yuantai Biological Technology Recent Development
11.14 GenScript Biotechnology
11.14.1 GenScript Biotechnology Company Details
11.14.2 GenScript Biotechnology Business Overview
11.14.3 GenScript Biotechnology Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.14.4 GenScript Biotechnology Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.14.5 GenScript Biotechnology Recent Development
11.15 WuXi Biologics
11.15.1 WuXi Biologics Company Details
11.15.2 WuXi Biologics Business Overview
11.15.3 WuXi Biologics Lipid Nanoparticles (LNPs) CDMO Service Introduction
11.15.4 WuXi Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
11.15.5 WuXi Biologics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of mRNA-LNP CDMO
Table 3. Key Players of siRNA-LNP CDMO
Table 4. Key Players of pDNA-LNP CDMO
Table 5. Key Players of Others
Table 6. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Region (2020-2025)
Table 10. Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Region (2026-2031)
Table 12. Lipid Nanoparticles (LNPs) CDMO Service Market Trends
Table 13. Lipid Nanoparticles (LNPs) CDMO Service Market Drivers
Table 14. Lipid Nanoparticles (LNPs) CDMO Service Market Challenges
Table 15. Lipid Nanoparticles (LNPs) CDMO Service Market Restraints
Table 16. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Players (2020-2025)
Table 18. Global Top Lipid Nanoparticles (LNPs) CDMO Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lipid Nanoparticles (LNPs) CDMO Service as of 2024)
Table 19. Ranking of Global Top Lipid Nanoparticles (LNPs) CDMO Service Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Lipid Nanoparticles (LNPs) CDMO Service Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Headquarters and Area Served
Table 22. Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Product and Application
Table 23. Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Type (2020-2025)
Table 27. Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Type (2026-2031)
Table 29. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Application (2020-2025)
Table 31. Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Application (2026-2031)
Table 33. North America Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 48. Evonik Company Details
Table 49. Evonik Business Overview
Table 50. Evonik Lipid Nanoparticles (LNPs) CDMO Service Product
Table 51. Evonik Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 52. Evonik Recent Development
Table 53. Lonza Company Details
Table 54. Lonza Business Overview
Table 55. Lonza Lipid Nanoparticles (LNPs) CDMO Service Product
Table 56. Lonza Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 57. Lonza Recent Development
Table 58. Rentschler Biopharma Company Details
Table 59. Rentschler Biopharma Business Overview
Table 60. Rentschler Biopharma Lipid Nanoparticles (LNPs) CDMO Service Product
Table 61. Rentschler Biopharma Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 62. Rentschler Biopharma Recent Development
Table 63. Samsung Biologics Company Details
Table 64. Samsung Biologics Business Overview
Table 65. Samsung Biologics Lipid Nanoparticles (LNPs) CDMO Service Product
Table 66. Samsung Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 67. Samsung Biologics Recent Development
Table 68. Hanmi Pharmaceutical Company Details
Table 69. Hanmi Pharmaceutical Business Overview
Table 70. Hanmi Pharmaceutical Lipid Nanoparticles (LNPs) CDMO Service Product
Table 71. Hanmi Pharmaceutical Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 72. Hanmi Pharmaceutical Recent Development
Table 73. Catalent Biologics Company Details
Table 74. Catalent Biologics Business Overview
Table 75. Catalent Biologics Lipid Nanoparticles (LNPs) CDMO Service Product
Table 76. Catalent Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 77. Catalent Biologics Recent Development
Table 78. FUJIFILM Pharmaceuticals Company Details
Table 79. FUJIFILM Pharmaceuticals Business Overview
Table 80. FUJIFILM Pharmaceuticals Lipid Nanoparticles (LNPs) CDMO Service Product
Table 81. FUJIFILM Pharmaceuticals Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 82. FUJIFILM Pharmaceuticals Recent Development
Table 83. CordenPharma Company Details
Table 84. CordenPharma Business Overview
Table 85. CordenPharma Lipid Nanoparticles (LNPs) CDMO Service Product
Table 86. CordenPharma Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 87. CordenPharma Recent Development
Table 88. ST Pharm Company Details
Table 89. ST Pharm Business Overview
Table 90. ST Pharm Lipid Nanoparticles (LNPs) CDMO Service Product
Table 91. ST Pharm Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 92. ST Pharm Recent Development
Table 93. eTheRNA Company Details
Table 94. eTheRNA Business Overview
Table 95. eTheRNA Lipid Nanoparticles (LNPs) CDMO Service Product
Table 96. eTheRNA Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 97. eTheRNA Recent Development
Table 98. Esco Aster Company Details
Table 99. Esco Aster Business Overview
Table 100. Esco Aster Lipid Nanoparticles (LNPs) CDMO Service Product
Table 101. Esco Aster Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 102. Esco Aster Recent Development
Table 103. Recipharm Company Details
Table 104. Recipharm Business Overview
Table 105. Recipharm Lipid Nanoparticles (LNPs) CDMO Service Product
Table 106. Recipharm Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 107. Recipharm Recent Development
Table 108. Yuantai Biological Technology Company Details
Table 109. Yuantai Biological Technology Business Overview
Table 110. Yuantai Biological Technology Lipid Nanoparticles (LNPs) CDMO Service Product
Table 111. Yuantai Biological Technology Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 112. Yuantai Biological Technology Recent Development
Table 113. GenScript Biotechnology Company Details
Table 114. GenScript Biotechnology Business Overview
Table 115. GenScript Biotechnology Lipid Nanoparticles (LNPs) CDMO Service Product
Table 116. GenScript Biotechnology Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 117. GenScript Biotechnology Recent Development
Table 118. WuXi Biologics Company Details
Table 119. WuXi Biologics Business Overview
Table 120. WuXi Biologics Lipid Nanoparticles (LNPs) CDMO Service Product
Table 121. WuXi Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 122. WuXi Biologics Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Lipid Nanoparticles (LNPs) CDMO Service Picture
Figure 2. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Type: 2024 VS 2031
Figure 4. mRNA-LNP CDMO Features
Figure 5. siRNA-LNP CDMO Features
Figure 6. pDNA-LNP CDMO Features
Figure 7. Others Features
Figure 8. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Application: 2024 VS 2031
Figure 10. Vaccines and Drugs Case Studies
Figure 11. Diagnostics and Medical Imaging Case Studies
Figure 12. Nanotherapeutics Case Studies
Figure 13. Others Case Studies
Figure 14. Lipid Nanoparticles (LNPs) CDMO Service Report Years Considered
Figure 15. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Region: 2024 VS 2031
Figure 18. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Players in 2024
Figure 19. Global Top Lipid Nanoparticles (LNPs) CDMO Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lipid Nanoparticles (LNPs) CDMO Service as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Lipid Nanoparticles (LNPs) CDMO Service Revenue in 2024
Figure 21. North America Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Lipid Nanoparticles (LNPs) CDMO Service Market Share by Country (2020-2031)
Figure 23. United States Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Share by Country (2020-2031)
Figure 27. Germany Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Share by Region (2020-2031)
Figure 35. China Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Share by Country (2020-2031)
Figure 43. Mexico Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Share by Country (2020-2031)
Figure 47. Turkey Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Evonik Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 51. Lonza Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 52. Rentschler Biopharma Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 53. Samsung Biologics Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 54. Hanmi Pharmaceutical Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 55. Catalent Biologics Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 56. FUJIFILM Pharmaceuticals Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 57. CordenPharma Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 58. ST Pharm Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 59. eTheRNA Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 60. Esco Aster Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 61. Recipharm Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 62. Yuantai Biological Technology Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 63. GenScript Biotechnology Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 64. WuXi Biologics Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of mRNA-LNP CDMO
Table 3. Key Players of siRNA-LNP CDMO
Table 4. Key Players of pDNA-LNP CDMO
Table 5. Key Players of Others
Table 6. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Region (2020-2025)
Table 10. Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Region (2026-2031)
Table 12. Lipid Nanoparticles (LNPs) CDMO Service Market Trends
Table 13. Lipid Nanoparticles (LNPs) CDMO Service Market Drivers
Table 14. Lipid Nanoparticles (LNPs) CDMO Service Market Challenges
Table 15. Lipid Nanoparticles (LNPs) CDMO Service Market Restraints
Table 16. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Players (2020-2025)
Table 18. Global Top Lipid Nanoparticles (LNPs) CDMO Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lipid Nanoparticles (LNPs) CDMO Service as of 2024)
Table 19. Ranking of Global Top Lipid Nanoparticles (LNPs) CDMO Service Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Lipid Nanoparticles (LNPs) CDMO Service Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Headquarters and Area Served
Table 22. Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Product and Application
Table 23. Global Key Players of Lipid Nanoparticles (LNPs) CDMO Service, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Type (2020-2025)
Table 27. Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Type (2026-2031)
Table 29. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Application (2020-2025)
Table 31. Global Lipid Nanoparticles (LNPs) CDMO Service Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Lipid Nanoparticles (LNPs) CDMO Service Revenue Market Share by Application (2026-2031)
Table 33. North America Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 48. Evonik Company Details
Table 49. Evonik Business Overview
Table 50. Evonik Lipid Nanoparticles (LNPs) CDMO Service Product
Table 51. Evonik Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 52. Evonik Recent Development
Table 53. Lonza Company Details
Table 54. Lonza Business Overview
Table 55. Lonza Lipid Nanoparticles (LNPs) CDMO Service Product
Table 56. Lonza Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 57. Lonza Recent Development
Table 58. Rentschler Biopharma Company Details
Table 59. Rentschler Biopharma Business Overview
Table 60. Rentschler Biopharma Lipid Nanoparticles (LNPs) CDMO Service Product
Table 61. Rentschler Biopharma Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 62. Rentschler Biopharma Recent Development
Table 63. Samsung Biologics Company Details
Table 64. Samsung Biologics Business Overview
Table 65. Samsung Biologics Lipid Nanoparticles (LNPs) CDMO Service Product
Table 66. Samsung Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 67. Samsung Biologics Recent Development
Table 68. Hanmi Pharmaceutical Company Details
Table 69. Hanmi Pharmaceutical Business Overview
Table 70. Hanmi Pharmaceutical Lipid Nanoparticles (LNPs) CDMO Service Product
Table 71. Hanmi Pharmaceutical Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 72. Hanmi Pharmaceutical Recent Development
Table 73. Catalent Biologics Company Details
Table 74. Catalent Biologics Business Overview
Table 75. Catalent Biologics Lipid Nanoparticles (LNPs) CDMO Service Product
Table 76. Catalent Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 77. Catalent Biologics Recent Development
Table 78. FUJIFILM Pharmaceuticals Company Details
Table 79. FUJIFILM Pharmaceuticals Business Overview
Table 80. FUJIFILM Pharmaceuticals Lipid Nanoparticles (LNPs) CDMO Service Product
Table 81. FUJIFILM Pharmaceuticals Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 82. FUJIFILM Pharmaceuticals Recent Development
Table 83. CordenPharma Company Details
Table 84. CordenPharma Business Overview
Table 85. CordenPharma Lipid Nanoparticles (LNPs) CDMO Service Product
Table 86. CordenPharma Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 87. CordenPharma Recent Development
Table 88. ST Pharm Company Details
Table 89. ST Pharm Business Overview
Table 90. ST Pharm Lipid Nanoparticles (LNPs) CDMO Service Product
Table 91. ST Pharm Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 92. ST Pharm Recent Development
Table 93. eTheRNA Company Details
Table 94. eTheRNA Business Overview
Table 95. eTheRNA Lipid Nanoparticles (LNPs) CDMO Service Product
Table 96. eTheRNA Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 97. eTheRNA Recent Development
Table 98. Esco Aster Company Details
Table 99. Esco Aster Business Overview
Table 100. Esco Aster Lipid Nanoparticles (LNPs) CDMO Service Product
Table 101. Esco Aster Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 102. Esco Aster Recent Development
Table 103. Recipharm Company Details
Table 104. Recipharm Business Overview
Table 105. Recipharm Lipid Nanoparticles (LNPs) CDMO Service Product
Table 106. Recipharm Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 107. Recipharm Recent Development
Table 108. Yuantai Biological Technology Company Details
Table 109. Yuantai Biological Technology Business Overview
Table 110. Yuantai Biological Technology Lipid Nanoparticles (LNPs) CDMO Service Product
Table 111. Yuantai Biological Technology Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 112. Yuantai Biological Technology Recent Development
Table 113. GenScript Biotechnology Company Details
Table 114. GenScript Biotechnology Business Overview
Table 115. GenScript Biotechnology Lipid Nanoparticles (LNPs) CDMO Service Product
Table 116. GenScript Biotechnology Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 117. GenScript Biotechnology Recent Development
Table 118. WuXi Biologics Company Details
Table 119. WuXi Biologics Business Overview
Table 120. WuXi Biologics Lipid Nanoparticles (LNPs) CDMO Service Product
Table 121. WuXi Biologics Revenue in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025) & (US$ Million)
Table 122. WuXi Biologics Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Lipid Nanoparticles (LNPs) CDMO Service Picture
Figure 2. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Type: 2024 VS 2031
Figure 4. mRNA-LNP CDMO Features
Figure 5. siRNA-LNP CDMO Features
Figure 6. pDNA-LNP CDMO Features
Figure 7. Others Features
Figure 8. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Application: 2024 VS 2031
Figure 10. Vaccines and Drugs Case Studies
Figure 11. Diagnostics and Medical Imaging Case Studies
Figure 12. Nanotherapeutics Case Studies
Figure 13. Others Case Studies
Figure 14. Lipid Nanoparticles (LNPs) CDMO Service Report Years Considered
Figure 15. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Lipid Nanoparticles (LNPs) CDMO Service Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Region: 2024 VS 2031
Figure 18. Global Lipid Nanoparticles (LNPs) CDMO Service Market Share by Players in 2024
Figure 19. Global Top Lipid Nanoparticles (LNPs) CDMO Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lipid Nanoparticles (LNPs) CDMO Service as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Lipid Nanoparticles (LNPs) CDMO Service Revenue in 2024
Figure 21. North America Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Lipid Nanoparticles (LNPs) CDMO Service Market Share by Country (2020-2031)
Figure 23. United States Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Lipid Nanoparticles (LNPs) CDMO Service Market Share by Country (2020-2031)
Figure 27. Germany Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Lipid Nanoparticles (LNPs) CDMO Service Market Share by Region (2020-2031)
Figure 35. China Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Lipid Nanoparticles (LNPs) CDMO Service Market Share by Country (2020-2031)
Figure 43. Mexico Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Service Market Share by Country (2020-2031)
Figure 47. Turkey Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Lipid Nanoparticles (LNPs) CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Evonik Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 51. Lonza Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 52. Rentschler Biopharma Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 53. Samsung Biologics Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 54. Hanmi Pharmaceutical Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 55. Catalent Biologics Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 56. FUJIFILM Pharmaceuticals Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 57. CordenPharma Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 58. ST Pharm Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 59. eTheRNA Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 60. Esco Aster Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 61. Recipharm Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 62. Yuantai Biological Technology Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 63. GenScript Biotechnology Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 64. WuXi Biologics Revenue Growth Rate in Lipid Nanoparticles (LNPs) CDMO Service Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232